Prexton Therapeutics’ Parkinson’s Assets First to Emerge from Merck KGAA Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.